Antinociceptive activity of combination of morphine and NMDA receptor antagonists depends on the inter-injection interval

European Journal of Pharmacology

Volumn 396, Issue 2-3, 2000, Pages 77-83

  Belozertseva, Irina V ^a   Dravolina, Olga A ^a   Neznanova, Olga N ^a   Danysz, Wojciech ^b   Bespalov, Anton Y ^a  

^a Inst P   (Russian Federation)

^b Merz+Co Eckenheimer L ^*  (Germany)

Author keywords

ACEA 1021; Antinociception; D CPPene (SDZ EAA 494); Memantine; Morphine; MRZ 2 576; MRZ 2 579; NMDA receptor antagonist

Indexed keywords

1 AMINO 1,3,3,5,5 PENTAMETHYL CYCLOHEXAN HYDROCHLORIDE; 4 (3 PHOSPHONOALLYL) 2 PIPERAZINECARBOXYLIC ACID; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; 8 CHLORO 4 HYDROXY 1 OXO 1,2 DIHYDROPYRIDALIONO(4,5B)QUINOLINE 5 OXIDE CHOLINE; MEMANTINE; MORPHINE; MRZ 2/576; MRZ 2/579; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG POTENTIATION; DRUG TOLERANCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TAIL FLICK TEST;

ANALGESICS; ANIMALS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; MALE; MEMANTINE; MICE; MORPHINE; PIPERAZINES; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0034686030     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00184-9     Document Type: Article

References (39)

1. Belozertseva I.V., Bespalov A.Y. Effects of NMDA receptor channel blockers, dizocilpine and memantine, on the development of opiate analgesic tolerance induced by repeated morphine exposures or social defeats in mice. Naunyn-Schmiedeberg's Arch. Pharmacol. 358:1998;270-274.
2. Belozertseva I., Danysz W., Bespalov A. Short-acting NMDA receptor antagonist MRZ 2/576 produces prolonged suppression of morphine withdrawal in mice. Naunyn-Schmiedeberg's Arch. Pharmacol. 361:2000;279-282.
3. Ben-Eliyahu S., Marek P., Vaccarino A.L., Mogil J.S., Sternberg W.F., Liebeskind J.C. The NMDA receptor antagonist MK-801 prevents long-lasting non-associative morphine tolerance in the rat. Brain Res. 575:1992;304-308.
4. Bespalov A.Y., Kudryashova M.F., Zvartau E.E. Prolongation of morphine analgesia by competitive NMDA receptor antagonist D-CPPene in rats. Eur. J. Pharmacol. 351:1998;299-305.
5. Bhargava H.N. Enhancement of morphine actions in morphine-naive and morphine-tolerant mice by LY 235959, a competitive antagonist of the NMDA receptor. Gen. Pharmacol. 28:1997;61-64.
6. Bilsky E.J., Inturrisi C.E., Sadee W., Hruby V.J., Porreca F. Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice. Pain. 68:1996;229-237.
7. Carlsson M.L. Are the disparate pharmacological profiles of competitive and uncompetitive NMDA antagonists due to different baseline activities of distinct glutamatergic pathways? J. Neural. Transm. Gen. Sect. 94:1993;1-10.
8. Chen L., Huang L.-Y.M. Sustained potentiation of NMDA receptor-mediated glutamate responses through activation of protein kinase C by a μ opioid. Neuron. 7:1991;319-326.
9. Colpaert F.C. System theory of pain and of opiate analgesia: no tolerance to opiates. Pharmacol. Rev. 48:1996;355-402.
10. Danysz W., Parsons C.G., Kornhuber J., Schmidt W.J., Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - preclinical studies. Neurosci. Biobehav. Rev. 21:1997;455-468.
11. Dunbar S., Yaksh T.L. Concurrent spinal infusion of MK801 blocks spinal tolerance and dependence induced by chronic intrathecal morphine in the rat. Anesthesiology. 84:1996;1177-1188.
12. Elliott K., Minami N., Kolesnikov Y.A., Pasternak G.W., Inturrisi C.E. The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain. 56:1994;69-75.
13. Gerber G., Kangrga I., Ryu P.D., Larew J.S., Randic M. Multiple effects of phorbol esters in the rat spinal dorsal horn. J. Neurosci. 9:1989;3606-3617.
14. Grass S., Hoffmann O., Xu X.J., Wiesenfeld-Hallin Z. N-methyl-D-aspartate receptor antagonists potentiate morphine's antinociceptive effect in the rat. Acta Physiol. Scand. 158:1996;269-273.
15. Herman B.H., Vocci F., Bridge P. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal - medication development issues for opiate addiction. Neuropsychopharmacology. 13:1995;269-293.
16. Herrling P.L., Emre M., Watkins J.C. D-CPPene (SDZ EAA-494) - a competitive NMDA receptor antagonist: pharmacology and results in humans. Herrling P.L. Excitatory Amino Acids - Clinical Results with Antagonists. 1997;7-21 Academic Press.
17. Kissin I., Brown P.T., Robinson C.A., Bradley E.L. Jr. Acute tolerance in morphine analgesia: continuous infusion and single injection in rats. Anesthesiology. 74:1991;166-171.
18. Kolesnikov Y.A., Ferkany J., Pasternak G.W. Blockade of mu and kappa 1 opioid analgesic tolerance by NPC17742, a novel NMDA antagonist. Life Sci. 53:1993;1489-1494.
19. Kolesnikov Y.A., Maccechini M.L., Pasternak G.W. 1-Aminocyclopropane carboxylic acid (ACPC) prevents mu and delta opioid tolerance. Life Sci. 55:1994;1393-1398.
20. Larcher A., Laulin J.P., Celerier E., Le Moal M., Simonnet G. Acute tolerance associated with a single opiate administration: involvement of N-methyl-D-aspartate-dependent pain facilitatory systems. Neuroscience. 84:1998;583-589.
21. Laulin J.P., Larcher A., Celerier E., Le Moal M., Simonnet G. Long lasting increased pain sensitivity in rat following exposure to heroin for the first time. Eur. J. Neurosci. 10:1998;782-785.
22. Laulin J.P., Celerier E., Larcher A., Le Moal M., Simonnet G. Opiate tolerance to daily heroin administration: an apparent phenomenon associated with enhanced pain sensitivity. Neuroscience. 89:1999;631-636.
23. Le Greves P., Huang W., Zhou Q., Thornwall M., Nyberg F. Acute effects of morphine on the expression of mRNAs for NMDA receptor subunits in the rat hippocampus, hypothalamus and spinal cord. Eur. J. Pharmacol. 341:1998;161-164.
24. Lipa S.M., Kavaliers M. Sex differences in the inhibitory effects of the NMDA antagonist, MK-801, on morphine and stress-induced analgesia. Brain Res. Bull. 24:1990;627-630.
25. Lutfy K., Weber E. Attenuation of nociceptive responses by ACEA-1021, a competitive NMDA receptor/glycine site antagonist, in the mice. Brain Res. 743:1996;17-23.
26. Lutfy K., Hurlbut D.E., Weber E. Blockade of morphine-induced analgesia and tolerance in mice by MK-801. Brain Res. 616:1993;83-88.
27. Marek P., Ben-Eliyahu S., Gold M., Liebeskind J.C. Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Res. 547:1991;77-81.
28. Marek P., Ben-Eliyahu S., Vaccarino A.L., Liebeskind J.C. Delayed application of MK-801 attenuates development of morphine tolerance in rats. Brain Res. 558:1991;163-165.
29. Nishiyama T., Yaksh T.L., Weber E. Effects of intrathecal NMDA and non-NMDA antagonists on acute thermal nociception and their interaction with morphine. Anesthesiology. 89:1998;715-722.
30. Parsons C.G., Danysz W., Quack G., Hartmann S., Lorenz B., Wollenburg C., Baran L., Przegalinski E., Kostowski W., Krzascik P., Chizh B., Headley P.M. Novel systemically-active antagonists of the glycine site of the NMDA receptor - electrophysiological, biochemical and behavioral characterization. J. Pharmacol. Exp. Ther. 283:1997;1264-1275.
31. Parsons C.G., Danysz W., Bartmann A., Spielmans P., Frankiewicz T., Hesselink M., Eilbacher B., Quack G. Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization. Neuropharmacology. 38:1999;85-108.
32. Saucier D.M., Kavaliers M. Antagonistic effects of the selective, competitive N-methyl-D-aspartate (NMDA) receptor antagonist, NPC 12626, on kappa opiate-induced analgesia in male deer mice. Brain Res. 637:1994;292-296.
33. Siegel S. Drug anticipation and drug tolerance. Lader M. The Psychopharmacology of Addiction. 1988;73-96 Oxford Univ. Press.
34. Tiseo P.J., Inturrisi C.E. Attenuation and reversal of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist, LY274614. J. Pharmacol. Exp. Ther. 264:1993;1090-1096.
35. Tiseo P.J., Cheng J., Pasternak G.W., Inturrisi C.E. Modulation of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY274614: assessment of opioid receptor changes. J. Pharmacol. Exp. Ther. 268:1994;195-201.
36. Trujillo K.A., Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science. 251:1991;85-87.
37. Urca G., Raigorodsky G. Behavioral classification of excitatory amino acids receptors in mouse spinal cord. Eur. J. Pharmacol. 153:1988;211-220.
38. Woodward R.M., Huettner J.E., Guastella J., Keana J.F., Weber E. In vitro pharmacology of ACEA-1021 and ACEA-1031: systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites. Mol. Pharmacol. 47:1995;568-581.
39. Young A.M. Effects of acute morphine pretreatment on the rate-decreasing and antagonist activity of naloxone. Psychopharmacology. 88:1986;201-208.